These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38258042)

  • 1. Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis.
    Nakamura T; Sasaki S; Sato Y; Harashima H
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11b
    Khalifa AM; Nakamura T; Sato Y; Harashima H
    Exp Hematol Oncol; 2024 Mar; 13(1):36. PubMed ID: 38553761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.
    Endo R; Ueda T; Nagaoki T; Shima N; Sato Y; Harashima H; Nakamura T
    J Control Release; 2024 Aug; 372():609-618. PubMed ID: 38942082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.
    Khalifa AM; Nakamura T; Sato Y; Sato T; Hyodo M; Hayakawa Y; Harashima H
    Int J Pharm; 2022 Aug; 624():122034. PubMed ID: 35863595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma.
    Nakamura T; Miyabe H; Hyodo M; Sato Y; Hayakawa Y; Harashima H
    J Control Release; 2015 Oct; 216():149-57. PubMed ID: 26282097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.
    Milling LE; Garafola D; Agarwal Y; Wu S; Thomas A; Donahue N; Adams J; Thai N; Suh H; Irvine DJ
    Cancer Immunol Res; 2022 Jan; 10(1):26-39. PubMed ID: 34686488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
    Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
    ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
    Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
    Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
    Czapla J; Drzyzga A; Matuszczak S; CichoĊ„ T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
    Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of STING in the treatment of non-small cell lung cancer.
    Tang W; Zhou W; Ji M; Yang X
    Cell Commun Signal; 2024 Apr; 22(1):202. PubMed ID: 38566036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.
    Wang-Bishop L; Kimmel BR; Ngwa VM; Madden MZ; Baljon JJ; Florian DC; Hanna A; Pastora LE; Sheehy TL; Kwiatkowski AJ; Wehbe M; Wen X; Becker KW; Garland KM; Schulman JA; Shae D; Edwards D; Wolf MM; Delapp R; Christov PP; Beckermann KE; Balko JM; Rathmell WK; Rathmell JC; Chen J; Wilson JT
    Sci Immunol; 2023 May; 8(83):eadd1153. PubMed ID: 37146128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation.
    Sun Y; Hu H; Liu Z; Xu J; Gao Y; Zhan X; Zhou S; Zhong W; Wu D; Wang P; Rao Z; Kong L; Zhou H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy.
    Hao Y; Ji Z; Zhou H; Wu D; Gu Z; Wang D; Ten Dijke P
    MedComm (2020); 2023 Aug; 4(4):e339. PubMed ID: 37560754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
    Lu X; Miao L; Gao W; Chen Z; McHugh KJ; Sun Y; Tochka Z; Tomasic S; Sadtler K; Hyacinthe A; Huang Y; Graf T; Hu Q; Sarmadi M; Langer R; Anderson DG; Jaklenec A
    Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation-Responsive PolyMOF Nanoparticles for Combination Photodynamic-Immunotherapy with Enhanced STING Activation.
    Zhou Q; Dutta D; Cao Y; Ge Z
    ACS Nano; 2023 May; 17(10):9374-9387. PubMed ID: 37141569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.
    Zhang P; Rashidi A; Zhao J; Silvers C; Wang H; Castro B; Ellingwood A; Han Y; Lopez-Rosas A; Zannikou M; Dmello C; Levine R; Xiao T; Cordero A; Sonabend AM; Balyasnikova IV; Lee-Chang C; Miska J; Lesniak MS
    Nat Commun; 2023 Mar; 14(1):1610. PubMed ID: 36959214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer.
    Dan Q; Yang Y; Ge H
    Curr Cancer Drug Targets; 2023; 23(5):354-362. PubMed ID: 36380440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.